A Multicenter, Prospective, Observational Study to Evaluate Ethanol-Induced Symptoms in Patients Receiving Docetaxel Chemotherapy
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose Several previous studies and case reports have reported ethanol-induced symptoms in patients receiving anticancer drugs containing ethanol. Most docetaxel formulations contain ethanol as a solvent. However, there are insufficient data on ethanol-induced symptoms when docetaxel-containing ethanol is administered. The primary purpose of this study was to investigate the frequency and pattern of ethanol-induced symptoms during and after docetaxel administration. The secondary purpose was to explore the risk factors for ethanol-induced symptoms. Materials and Methods This was a prospective, multicenter, observational study. The participants filled out ethanol-induced symptom questionnaire on the day of chemotherapy and the following day. Results Data from 451 patients were analyzed. The overall occurrence rate of ethanol-induced symptoms was 44.3% (200/451 patients). The occurrence rate of facial flushing was highest at 19.7% (89/451 patients), followed by nausea in 18.2% (82/451 patients), and dizziness in 17.5% (79/451 patients). Although infrequent, unsteady walking and impaired balance occurred in 4.2% and 3.3% of patients, respectively. Female sex, presence of underlying disease, younger age, docetaxel dose, and docetaxel-containing ethanol amount were significantly associated with the occurrence of ethanol-induced symptoms. Conclusion The occurrence of ethanol-induced symptoms was not low in patients receiving docetaxel-containing ethanol. Physicians need to pay more attention to the occurrence of ethanol-induced symptoms and prescribe ethanol-free or low-ethanol-containing formulations to high-risk patients.
Abstract
Purpose Several previous studies and case reports have reported ethanol-induced symptoms in patients receiving anticancer drugs containing ethanol. Most docetaxel formulations contain ethanol as a solvent. However, there are insufficient data on ethanol-induced symptoms when docetaxel-containing ethanol is administered. The primary purpose of this study was to investigate the frequency and pattern of ethanol-induced symptoms during and after docetaxel administration. The secondary purpose was to explore the risk factors for ethanol-induced symptoms. Materials and Methods This was a prospective, multicenter, observational study. The participants filled out ethanol-induced symptom questionnaire on the day of chemotherapy and the following day. Results Data from 451 patients were analyzed. The overall occurrence rate of ethanol-induced symptoms was 44.3% (200/451 patients). The occurrence rate of facial flushing was highest at 19.7% (89/451 patients), followed by nausea in 18.2% (82/451 patients), and dizziness in 17.5% (79/451 patients). Although infrequent, unsteady walking and impaired balance occurred in 4.2% and 3.3% of patients, respectively. Female sex, presence of underlying disease, younger age, docetaxel dose, and docetaxel-containing ethanol amount were significantly associated with the occurrence of ethanol-induced symptoms. Conclusion The occurrence of ethanol-induced symptoms was not low in patients receiving docetaxel-containing ethanol. Physicians need to pay more attention to the occurrence of ethanol-induced symptoms and prescribe ethanol-free or low-ethanol-containing formulations to high-risk patients.
참고문헌 (21)
- Fries H, "A different kind of relapse : ethanol as an additive in chemotherapy formulations", Oncol Res Treat, 42, pp.350~353 (2019)
- Aomori T, "Effect of ethanol in paclitaxel injections on the ethanol concentration in exhaled breath", Drugs R D, 12, pp.165~170 (2012)
- Diez-Fernandez R, "Ethanol-induced symptoms in patients receiving gemcitabine diluted from a concentrate for solution for infusion containing ethanol", J Oncol Pharm Pract, 24, pp.511~516 (2018)
- Mirza A, "Alcohol intoxication with the new formulation of docetaxel", Clin Oncol(R Coll Radiol), 23, pp.560~561 (2011)
- Webster LK, "Plasma alcohol concentrations in patients following paclitaxel infusion", Cancer Chemother Pharmacol, 37, pp.499~501 (1996)
- U.S. Food and Drug Administration, "FDA Drug Safety Communications: FDA warns that cancer drug docetaxel may cause symptoms of alcohol intoxication after treatment", U.S. Food and Drug Administration, ~ (2016)
- Vonghia L, "Acute alcohol intoxication", Eur J Intern Med, 19, pp.561~567 (2008)
- Fleiss JL, "Statistical methods for rates and proportions" (2013), John Wiley & Sons
- Newcombe RG, "Two-sided confidence intervals for the single proportion : comparison of seven methods", Stat Med, 17, pp.857~872 (1998)
- Searle J, "Alcohol calculations and their uncertainty", Med Sci Law, 55, pp.58~64 (2015)
- Hiver Q, "Ethanol exposure during the intravenous administration of chemotherapeutic drugs : an analysis of clinical practice and a literature review", JCO Oncol Pract, 18, pp.e710~20 (2022)
- Yagi T, "Aldehyde dehydrogenase 2 genotype in tolerability of alcohol contained in paclitaxel in Japanese breast cancer patients", Breast Cancer, 26, pp.229~234 (2019)
- Iwahashi K, "Ethanol metabolism, toxicity and genetic polymorphism", Addict Biol, 3, pp.249~259 (1998)
- Cederbaum AI, "Alcohol metabolism", Clin Liver Dis, 16, pp.667~685 (2012)
- Oscar-Berman M, "Alcohol : effects on neurobehavioral functions and the brain", Neuropsychol Rev, 17, pp.239~257 (2007)
- Baraona E, "Gender differences in pharmacokinetics of alcohol", Alcohol Clin Exp Res, 25, pp.502~507 (2001)
- Kwo PY, "Gender differences in alcohol metabolism : relationship to liver volume and effect of adjusting for body mass", Gastroenterology, 115, pp.1552~1557 (1998)
- Meier P, "Age, alcohol metabolism and liver disease", Curr Opin Clin Nutr Metab Care, 11, pp.21~26 (2008)
- Thomasson HR, "Recent development in alcoholism. Vol. 12", pp.163~179 (2002), Springer
- Weathermon R, "Alcohol and medication interactions", Alcohol Res Health, 23, pp.40~54 (1999)
- Lynch T, "The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects", Am Fam Physician, 76, pp.391~396 (2007)